A real-world study of tirzepatide for weight loss in adults without diabetes mellitus
Authors' conclusion
Low-dose tirzepatide resulted in clinically meaningful short-term weight loss and favorable metabolic effects, supporting its effectiveness and tolerability in real-world practice.
Study context
- Population
- Adults with obesity without DM
- Participants
- 115 adults
- Outcome
- Body weight change
- Follow-up
- Week 12
Methodological detailsmulticentre, single-group
- Multicentre
- Single-group
Main finding
As reported in the abstract
Mean body weight decrease
8.2 ± 4.9 kg
Body weight change (%)
−7.3% ±4.4%
BMI reduction
2.8 ± 1.7 kg/m²
≥5% weight loss
46.1%
Observational data: associations, not effects.
Further findings
Metabolic parameters · baseline to week 12
- HbA1c decreased (from → to)
- 5.6 ± 0.4% to 5.4 ± 0.3%
- LDL-C decreased (from → to)
- 113 ± 30.4 to 106 ± 28 mg/dL
- TG decreased (from → to)
- 123.6 ± 56.1 to 119.2 ± 44.5 mg/dL
- HDL-C and eGFR remained unchanged
Safety
Adverse events and discontinuation
- Nausea (most common AE)
- 7.8%
- Treatment discontinuation, mainly in prior GLP-1 RA users
- 10.4%
Original publication
A real-world study of tirzepatide for weight loss in adults without diabetes mellitus. Int J Obes (Lond). Published 8 December 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →